ReviewBiosensors2025
Plasmonic Biosensors in Cancer-Associated miRNA Detection.
Review in Biosensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Conducting Polymer-Nanomaterial Hybrids for Cancer Diagnostics.Biosensors · 2026Review
- Recent Progress in Nanophotonics for Green Energy, Medicine, Healthcare, and Optical Computing Applications.Materials (Basel, Switzerland) · 2026Review
- Single-Molecule Monitoring of Nucleic Acid Dynamics Using Raman Correlation Spectroscopy in Plasmonic Nanowells.ACS nano · 2025Article
- CRISPR-based platforms for detecting tumor-associated genetic materials in clinical samples.Bioanalysis · 2025Review
- Functionalized Carbon Nanotubes: Emerging Nanomaterials for Enhanced Cancer Diagnosis and Imaging.Molecules (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Cancer is one of the most lethal diseases and has distinct variants that affect over 60 organs in the human body. The necessity of advanced methodologies for the early diagnosis of cancer has grown over the past decades. Among various biomarkers, microRNAs (miRNAs) have emerged as highly specific and minimally invasive indicators for cancer detection, prognosis, and treatment monitoring. Their stability in biological fluids and their critical role in gene regulation make them valuable targets for diagnostic applications. Plasmonic biosensors have gained massive attention owing to their unique optical properties, such as surface plasmon resonance, making them promising tools for the sensitive and selective analysis of cancer-associated biomarkers. In contrast to previous reviews, this work offers a comprehensive overview of advancements from approximately the past five years, particularly in the detection of cancer-associated miRNAs. It emphasizes emerging plasmonic sensing strategies, integration with novel nanomaterials, and enhanced signal amplification techniques. By focusing on these recent innovations, this review provides new insights into the potential of plasmonic biosensors to improve cancer diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.